Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource

ISBN: 0-12-819468-5

Language: English

UID:

Format: 1 online resource

ISBN: 0-12-819468-5

Language: English

UID:

Format: 1 online resource

ISBN: 0-12-819468-5

Language: English

UID:

Format: 1 online resource (330 pages) : , color illustrations

ISBN: 0-12-811398-7

Note: Front Cover -- Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to Bedside -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Epidemiology of LUTS and BPH -- Economic Impact of BPH and LUTS -- Risk Factors for BPH Development -- Age -- Genetics -- Sex Steroid Hormones -- Metabolic Syndrome -- Cardiovascular Disease -- Obesity -- Diabetes and Alterations in Glucose Homeostasis -- Lipids -- Physical Activity -- Alcohol -- Smoking -- Inflammation -- Race -- References -- Chapter 2: Pathologic Triggers Related to LUTS and BPH -- Introduction -- Etiology -- Hyperplasia -- Role of Inflammation -- Prostatic Immune Cells and Inflammation -- BPH and Prostatic Inflammation -- Clinical Evidence -- Molecular Pathways -- Hormonal Pathways -- Metabolic Syndrome, Inflammation, and BPH -- Inflammation and BPH Progression -- Biomarkers of Prostatic Inflammation -- References -- Further Reading -- Chapter 3: The Relationship Between Inflammation and LUTS/BPH -- Introduction -- Pathophysiology -- The Immunochemical Pattern of BPH -- The Inflammatory Pattern of BPH -- The Origin of Chronic Prostate Inflammation -- The Role of Inflammatory Cytokines -- Chronic Inflammation and LUTS -- Prostate Inflammation and BPH Progression -- Prostate Inflammation and LUTS Deterioration -- Prostate Inflammation and Acute Urinary Retention -- Diagnostic Methods for Chronic Prostate Inflammation -- The Role of Biomarkers -- Concurrent Prostate Calcifications -- Medical History of Chronic Urinary Tract Infections -- Metabolic Syndrome-A More Recent Trend in the Etiology of LUTS/BPH. The Connection With Prostatic Inflammation -- Prostate Inflammation and Its Impact on LUTS Medication -- Conclusions -- References -- Further Reading -- Chapter 4: Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. , Anatomy and Physiology of Erectile Dysfunction -- Epidemiology and Risk Factors of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction -- Age -- Sedentary Lifestyle and Lack of Exercise -- Cigarette Smoking -- Excessive Alcohol Intake -- Depression -- Hypertension and Cardiovascular Disease -- Hyperlipidemia -- Type 2 Diabetes Mellitus -- Obesity/Waist Circumference -- Hypogonadism -- Genetic Predisposition -- Pathophysiology of LUTS/BPH and ED -- Etiology and Clinical Aspects of LUTS/BPH and ED -- Second-Line Evaluation -- Treatment of LUTS/BPH and ED -- Education and Lifestyle Modifications -- Phosphodiesterase Type 5 Inhibitors -- Tadalafil -- Efficacy of Action of PDE5I Monotherapy in ED-LUTS/BPH -- Combined Therapy With α-Adrenergic Antagonists and PDE5i -- Other PDE5I Therapies (Not Approved by Current Guidelines for ED-LUTS/BPH) -- Sildenafil -- Vardenafil -- Avanafil -- Mirodenafil -- Udenafil -- Effects of Drugs Used for LUTS on Erectile Function -- Conclusive Remarks -- References -- Chapter 5: Metabolic Syndrome and LUTS/BPH -- Introduction -- Metabolic Syndrome: Definition and Prevalence -- MetS and BPH: Preclinical Evidences and Pathophysiology -- MetS and LUTS/BPE: The Role of Inflammation -- Prostate Size and Shape: The Influence of MetS -- The Correlation Between MetS and LUTS -- Diet and Lifestyle in Men With MetS and LUTS Due to BPE -- Basis for Medical Treatment in Men With MetS and LUTS/BPE -- The Impact of MetS on the Outcomes of BPH Surgery -- Conclusions -- References -- Chapter 6: Diagnostic Work-up of LUTS/BPH: From Standard to New Perspectives -- Introduction -- Diagnostic Workup of LUTS/BPH -- Standard Diagnostic Tests -- History -- Symptom Questionnaires -- Frequency Volume Charts and Bladder Diaries -- Physical Examination and Digital-Rectal Examination -- Urinalysis -- Blood Analysis. , PVR Urine -- Uroflowmetry -- Imaging -- Urethro-Cystoscopy -- Computer-Urodynamic Investigation -- New Diagnostic Perspectives -- Ultrasound Measurement of IPP -- Ultrasound Measurement of DWT -- References -- Further Reading -- Chapter 7: Phytotherapy in Benign Prostatic Hyperplasia -- Introduction -- Serenoa Repens -- Mechanism of Action -- Variability of Products and Extraction Techniques -- Clinical Studies -- Safety Profile -- Conclusion -- Pygenum Africanum -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Urtica Dioica -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Cucurbita Pepo -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Hypoxis Rooperi -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Rye Grass Pollen -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Conclusion -- References -- Chapter 8: Medical Aspects of the Treatment of LUTS/BPH: Alpha-Blockers -- Introduction -- Pathophysiology and Mechanisms of Action of Alpha-Blockers in BPH -- Pathophysiology of LUTS/BPH/BPO: Reviewing Alpha-Adrenoreceptors as a Valuable Therapeutic Target -- Potential Action of Alpha-Blockers on BPO -- Potential Effects of Alpha-Blockers on Storage Symptoms and Bladder Function -- Potential Effects of Alpha-Blockers on Nocturia -- Types of Alpha-Adrenergic Blockers: Family Members -- Efficacy -- Global Efficacy on LUTS (IPSS), Quality of Life, and Placebo Effect -- Effects on BPO (Qmax, Urodynamics, and Postvoid Residuals) -- Efficacy on the Long Term and Treatment Adherence -- Intermittent Treatment -- Dose Adjustments -- Safety and Tolerability -- Clinical Use -- General Indications/Single Therapy -- Associations -- Conclusion -- References. , Chapter 9: Medical Aspects of the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: 5-Alpha Reducta ... -- Mechanism of Action -- Testosterone and Dihydrotestosterone -- 5-Alpha Reductase Enzyme Family -- Rationale for 5-Alpha Reductase Inhibition in BPH -- 5-Alpha Reductase Inhibitors -- Finasteride -- Dutasteride -- 5-ARI for the Treatment of BPH -- Indications for Treatment of BPH With 5-ARI -- Clinical Effects of BPH Treatment With 5-ARI -- Finasteride Versus Dutasteride for the Treatment of BPH -- Sexual Side Effects of 5-Alpha Reductase Inhibitor Use -- Combination Therapy With 5-ARI and Alpha-1 Adrenergic Receptor Blockers for the Treatment of BPH -- 5-ARI for Hematuria and Bleeding During Transurethral Resection of the Prostate in Men With BPH -- 5-ARI for the Prevention and Treatment of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Prevention of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Treatment of Prostate Cancer -- References -- Chapter 10: Medical Aspects of the Treatment of LUTS/BPH: Antimuscarinic and β3-Agonists -- Keypoints -- Introduction -- Antimuscarinics -- Mechanism of Action -- Efficacy -- Adverse Events -- β3-Agonists -- Mechanism of Action -- Efficacy -- Adverse Events -- Conclusions -- References -- Chapter 11: Medical Aspects of the Treatment of LUTS/BPH: Combination Therapies -- Introduction -- AB+5ARI -- Anticholinergic Agents and AB -- Tolterodine and AB -- Solifenacin Succinate and AB -- Fesoterodine and AB -- β3-Adrenoreceptor Agonist Mirabegron and AB -- Phosphodiesterase-Type-5 Inhibitors and 5ARI or AB -- Plant Extracts/Phytotherapy and Other Agents -- References -- Chapter 12: Surgical Management of LUTS/BPH: TURP vs. Open Prostatectomy -- History of Surgical Treatment for Benign Prostatic Hyperplasia (BPH) -- Pathophysiology of BPH. , Epidemiology and Socioeconomic Burden of Surgical Treatment for BPH -- Factors Affecting Choice of Surgery Type -- Prostate Size -- Surgeon Preference and Hospital Setting -- Patient Age -- Prostatectomy -- Simple Prostatectomy -- Robot-Assisted Laparoscopic Approaches -- TUR of the Prostate -- Monopolar TURP -- Bipolar TURP -- Outcomes -- Symptoms -- Dysuria -- Urgency -- IPSS Improvement -- Quality of Life -- Physiological Measures -- Peak Flow Rate Improvement -- Residual Urinary Volume Reduction -- Perioperative Outcomes -- Bleeding -- Resected Prostate Weight -- Postoperative Fever -- Time to Catheter Removal -- Hospital Stay and Return Time to Work -- Urinary Tract Infection -- Epididymitis -- Retreatment Rate -- Re-operation -- Adverse Events -- Incontinence -- Impotence -- Bladder Neck Contracture -- TUR Syndrome -- Conclusion -- References -- Chapter 13: Surgical Treatment for LUTS/BPH: Laser Devices -- Introduction -- Lasers Typically Used for Vaporization -- GreenLight Laser -- Diode Lasers -- Lasers Typically Used for Resection/Enucleation -- Thulium Lasers -- Holmium:YAG Lasers -- Enucleation for BPO: Techniques and Results -- Holmium Laser Enucleation of the Prostate -- Principles of Surgical Technique -- Results -- Complications -- Thulium Laser Enucleation of the Prostate (ThuLEP) -- Principles of Surgical Technique -- Results -- Complications -- Greenlight Laser Enucleation of the Prostate (GreenLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Diode Laser Enucleation of the Prostate (DiLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Eraser Laser Enucleation of the Prostate (ELEP) -- Principles of Surgical Technique -- Results -- Complications -- Laser Ablation for Benign Prostatic Enlargement: Techniques and Results. , Holmium Laser Ablation of the Prostate.

Additional Edition: ISBN 0-12-811397-9

Language: English

UID:

Format: 1 online resource (330 pages) : , color illustrations

ISBN: 0-12-811398-7

Note: Front Cover -- Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to Bedside -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Epidemiology of LUTS and BPH -- Economic Impact of BPH and LUTS -- Risk Factors for BPH Development -- Age -- Genetics -- Sex Steroid Hormones -- Metabolic Syndrome -- Cardiovascular Disease -- Obesity -- Diabetes and Alterations in Glucose Homeostasis -- Lipids -- Physical Activity -- Alcohol -- Smoking -- Inflammation -- Race -- References -- Chapter 2: Pathologic Triggers Related to LUTS and BPH -- Introduction -- Etiology -- Hyperplasia -- Role of Inflammation -- Prostatic Immune Cells and Inflammation -- BPH and Prostatic Inflammation -- Clinical Evidence -- Molecular Pathways -- Hormonal Pathways -- Metabolic Syndrome, Inflammation, and BPH -- Inflammation and BPH Progression -- Biomarkers of Prostatic Inflammation -- References -- Further Reading -- Chapter 3: The Relationship Between Inflammation and LUTS/BPH -- Introduction -- Pathophysiology -- The Immunochemical Pattern of BPH -- The Inflammatory Pattern of BPH -- The Origin of Chronic Prostate Inflammation -- The Role of Inflammatory Cytokines -- Chronic Inflammation and LUTS -- Prostate Inflammation and BPH Progression -- Prostate Inflammation and LUTS Deterioration -- Prostate Inflammation and Acute Urinary Retention -- Diagnostic Methods for Chronic Prostate Inflammation -- The Role of Biomarkers -- Concurrent Prostate Calcifications -- Medical History of Chronic Urinary Tract Infections -- Metabolic Syndrome-A More Recent Trend in the Etiology of LUTS/BPH. The Connection With Prostatic Inflammation -- Prostate Inflammation and Its Impact on LUTS Medication -- Conclusions -- References -- Further Reading -- Chapter 4: Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. , Anatomy and Physiology of Erectile Dysfunction -- Epidemiology and Risk Factors of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction -- Age -- Sedentary Lifestyle and Lack of Exercise -- Cigarette Smoking -- Excessive Alcohol Intake -- Depression -- Hypertension and Cardiovascular Disease -- Hyperlipidemia -- Type 2 Diabetes Mellitus -- Obesity/Waist Circumference -- Hypogonadism -- Genetic Predisposition -- Pathophysiology of LUTS/BPH and ED -- Etiology and Clinical Aspects of LUTS/BPH and ED -- Second-Line Evaluation -- Treatment of LUTS/BPH and ED -- Education and Lifestyle Modifications -- Phosphodiesterase Type 5 Inhibitors -- Tadalafil -- Efficacy of Action of PDE5I Monotherapy in ED-LUTS/BPH -- Combined Therapy With α-Adrenergic Antagonists and PDE5i -- Other PDE5I Therapies (Not Approved by Current Guidelines for ED-LUTS/BPH) -- Sildenafil -- Vardenafil -- Avanafil -- Mirodenafil -- Udenafil -- Effects of Drugs Used for LUTS on Erectile Function -- Conclusive Remarks -- References -- Chapter 5: Metabolic Syndrome and LUTS/BPH -- Introduction -- Metabolic Syndrome: Definition and Prevalence -- MetS and BPH: Preclinical Evidences and Pathophysiology -- MetS and LUTS/BPE: The Role of Inflammation -- Prostate Size and Shape: The Influence of MetS -- The Correlation Between MetS and LUTS -- Diet and Lifestyle in Men With MetS and LUTS Due to BPE -- Basis for Medical Treatment in Men With MetS and LUTS/BPE -- The Impact of MetS on the Outcomes of BPH Surgery -- Conclusions -- References -- Chapter 6: Diagnostic Work-up of LUTS/BPH: From Standard to New Perspectives -- Introduction -- Diagnostic Workup of LUTS/BPH -- Standard Diagnostic Tests -- History -- Symptom Questionnaires -- Frequency Volume Charts and Bladder Diaries -- Physical Examination and Digital-Rectal Examination -- Urinalysis -- Blood Analysis. , PVR Urine -- Uroflowmetry -- Imaging -- Urethro-Cystoscopy -- Computer-Urodynamic Investigation -- New Diagnostic Perspectives -- Ultrasound Measurement of IPP -- Ultrasound Measurement of DWT -- References -- Further Reading -- Chapter 7: Phytotherapy in Benign Prostatic Hyperplasia -- Introduction -- Serenoa Repens -- Mechanism of Action -- Variability of Products and Extraction Techniques -- Clinical Studies -- Safety Profile -- Conclusion -- Pygenum Africanum -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Urtica Dioica -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Cucurbita Pepo -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Hypoxis Rooperi -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Rye Grass Pollen -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Conclusion -- References -- Chapter 8: Medical Aspects of the Treatment of LUTS/BPH: Alpha-Blockers -- Introduction -- Pathophysiology and Mechanisms of Action of Alpha-Blockers in BPH -- Pathophysiology of LUTS/BPH/BPO: Reviewing Alpha-Adrenoreceptors as a Valuable Therapeutic Target -- Potential Action of Alpha-Blockers on BPO -- Potential Effects of Alpha-Blockers on Storage Symptoms and Bladder Function -- Potential Effects of Alpha-Blockers on Nocturia -- Types of Alpha-Adrenergic Blockers: Family Members -- Efficacy -- Global Efficacy on LUTS (IPSS), Quality of Life, and Placebo Effect -- Effects on BPO (Qmax, Urodynamics, and Postvoid Residuals) -- Efficacy on the Long Term and Treatment Adherence -- Intermittent Treatment -- Dose Adjustments -- Safety and Tolerability -- Clinical Use -- General Indications/Single Therapy -- Associations -- Conclusion -- References. , Chapter 9: Medical Aspects of the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: 5-Alpha Reducta ... -- Mechanism of Action -- Testosterone and Dihydrotestosterone -- 5-Alpha Reductase Enzyme Family -- Rationale for 5-Alpha Reductase Inhibition in BPH -- 5-Alpha Reductase Inhibitors -- Finasteride -- Dutasteride -- 5-ARI for the Treatment of BPH -- Indications for Treatment of BPH With 5-ARI -- Clinical Effects of BPH Treatment With 5-ARI -- Finasteride Versus Dutasteride for the Treatment of BPH -- Sexual Side Effects of 5-Alpha Reductase Inhibitor Use -- Combination Therapy With 5-ARI and Alpha-1 Adrenergic Receptor Blockers for the Treatment of BPH -- 5-ARI for Hematuria and Bleeding During Transurethral Resection of the Prostate in Men With BPH -- 5-ARI for the Prevention and Treatment of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Prevention of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Treatment of Prostate Cancer -- References -- Chapter 10: Medical Aspects of the Treatment of LUTS/BPH: Antimuscarinic and β3-Agonists -- Keypoints -- Introduction -- Antimuscarinics -- Mechanism of Action -- Efficacy -- Adverse Events -- β3-Agonists -- Mechanism of Action -- Efficacy -- Adverse Events -- Conclusions -- References -- Chapter 11: Medical Aspects of the Treatment of LUTS/BPH: Combination Therapies -- Introduction -- AB+5ARI -- Anticholinergic Agents and AB -- Tolterodine and AB -- Solifenacin Succinate and AB -- Fesoterodine and AB -- β3-Adrenoreceptor Agonist Mirabegron and AB -- Phosphodiesterase-Type-5 Inhibitors and 5ARI or AB -- Plant Extracts/Phytotherapy and Other Agents -- References -- Chapter 12: Surgical Management of LUTS/BPH: TURP vs. Open Prostatectomy -- History of Surgical Treatment for Benign Prostatic Hyperplasia (BPH) -- Pathophysiology of BPH. , Epidemiology and Socioeconomic Burden of Surgical Treatment for BPH -- Factors Affecting Choice of Surgery Type -- Prostate Size -- Surgeon Preference and Hospital Setting -- Patient Age -- Prostatectomy -- Simple Prostatectomy -- Robot-Assisted Laparoscopic Approaches -- TUR of the Prostate -- Monopolar TURP -- Bipolar TURP -- Outcomes -- Symptoms -- Dysuria -- Urgency -- IPSS Improvement -- Quality of Life -- Physiological Measures -- Peak Flow Rate Improvement -- Residual Urinary Volume Reduction -- Perioperative Outcomes -- Bleeding -- Resected Prostate Weight -- Postoperative Fever -- Time to Catheter Removal -- Hospital Stay and Return Time to Work -- Urinary Tract Infection -- Epididymitis -- Retreatment Rate -- Re-operation -- Adverse Events -- Incontinence -- Impotence -- Bladder Neck Contracture -- TUR Syndrome -- Conclusion -- References -- Chapter 13: Surgical Treatment for LUTS/BPH: Laser Devices -- Introduction -- Lasers Typically Used for Vaporization -- GreenLight Laser -- Diode Lasers -- Lasers Typically Used for Resection/Enucleation -- Thulium Lasers -- Holmium:YAG Lasers -- Enucleation for BPO: Techniques and Results -- Holmium Laser Enucleation of the Prostate -- Principles of Surgical Technique -- Results -- Complications -- Thulium Laser Enucleation of the Prostate (ThuLEP) -- Principles of Surgical Technique -- Results -- Complications -- Greenlight Laser Enucleation of the Prostate (GreenLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Diode Laser Enucleation of the Prostate (DiLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Eraser Laser Enucleation of the Prostate (ELEP) -- Principles of Surgical Technique -- Results -- Complications -- Laser Ablation for Benign Prostatic Enlargement: Techniques and Results. , Holmium Laser Ablation of the Prostate.

Additional Edition: ISBN 0-12-811397-9

Language: English

UID:

Format: VI, 445 p. 98 illus., 91 illus. in color. , online resource.

Edition: 1st ed. 2022.

ISBN: 9783031120497

Series Statement: Management of Urology,

Content: Andrology & Sexual Medicine is a comprehensive source for urologists, andrologists, sexologists and general practitioners. It contains general and up-to-date information about almost all topics within andrology and sexual medicine, and is a unique source that can be used for both exams and general daily practice. Easily accessible to clinicians and researchers and specialists, it tackles the controversial and complex topics of andrology and sexual medicine for urologists.

Note: Introduction, Etiology and Epidemiology of Sexual Dysfunctions in Men and Women -- Diagnosis of Male Sexual Dysfunction -- Erectile Dysfunction-from diagnosis to treatment -- Ejaculation & Male Orgasmic Disorders -- Andrologic Emergencies -- Peyronie's Disease and Penile Curvature -- Reconstructive Andrologic Surgery -- Penile Rehabilitation -- Pathophysiology and Clinical Aspects of Sexual Dysfunction in Women -- Arousal, Desire and Pain Disorders in Women -- Male Infertility -- Contraception -- Male Hypogonadism -- Sexually Transmitted Diseases -- Penile Cancer -- Testosterone Therapy. .

In: Springer Nature eBook

Additional Edition: Printed edition: ISBN 9783031120480

Additional Edition: Printed edition: ISBN 9783031120503

Additional Edition: Printed edition: ISBN 9783031120510

Language: English

DOI: 10.1007/978-3-031-12049-7

URL: https://doi.org/10.1007/978-3-031-12049-7

UID:

Format: 1 Online-Ressource (VI, 445 p. 98 illus., 91 illus. in color).

Edition: 1st ed. 2022

ISBN: 978-3-031-12049-7

Series Statement: Management of Urology

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-12048-0

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-12050-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-12051-0

Language: English

DOI: 10.1007/978-3-031-12049-7

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (VI, 445 p. 98 illus., 91 illus. in color).

Edition: 1st ed. 2022

ISBN: 978-3-031-12049-7

Series Statement: Management of Urology

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-12048-0

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-12050-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-12051-0

Language: English

DOI: 10.1007/978-3-031-12049-7

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (330 pages) : , color illustrations

ISBN: 0-12-811398-7

Note: Front Cover -- Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to Bedside -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Epidemiology of LUTS and BPH -- Economic Impact of BPH and LUTS -- Risk Factors for BPH Development -- Age -- Genetics -- Sex Steroid Hormones -- Metabolic Syndrome -- Cardiovascular Disease -- Obesity -- Diabetes and Alterations in Glucose Homeostasis -- Lipids -- Physical Activity -- Alcohol -- Smoking -- Inflammation -- Race -- References -- Chapter 2: Pathologic Triggers Related to LUTS and BPH -- Introduction -- Etiology -- Hyperplasia -- Role of Inflammation -- Prostatic Immune Cells and Inflammation -- BPH and Prostatic Inflammation -- Clinical Evidence -- Molecular Pathways -- Hormonal Pathways -- Metabolic Syndrome, Inflammation, and BPH -- Inflammation and BPH Progression -- Biomarkers of Prostatic Inflammation -- References -- Further Reading -- Chapter 3: The Relationship Between Inflammation and LUTS/BPH -- Introduction -- Pathophysiology -- The Immunochemical Pattern of BPH -- The Inflammatory Pattern of BPH -- The Origin of Chronic Prostate Inflammation -- The Role of Inflammatory Cytokines -- Chronic Inflammation and LUTS -- Prostate Inflammation and BPH Progression -- Prostate Inflammation and LUTS Deterioration -- Prostate Inflammation and Acute Urinary Retention -- Diagnostic Methods for Chronic Prostate Inflammation -- The Role of Biomarkers -- Concurrent Prostate Calcifications -- Medical History of Chronic Urinary Tract Infections -- Metabolic Syndrome-A More Recent Trend in the Etiology of LUTS/BPH. The Connection With Prostatic Inflammation -- Prostate Inflammation and Its Impact on LUTS Medication -- Conclusions -- References -- Further Reading -- Chapter 4: Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. , Anatomy and Physiology of Erectile Dysfunction -- Epidemiology and Risk Factors of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction -- Age -- Sedentary Lifestyle and Lack of Exercise -- Cigarette Smoking -- Excessive Alcohol Intake -- Depression -- Hypertension and Cardiovascular Disease -- Hyperlipidemia -- Type 2 Diabetes Mellitus -- Obesity/Waist Circumference -- Hypogonadism -- Genetic Predisposition -- Pathophysiology of LUTS/BPH and ED -- Etiology and Clinical Aspects of LUTS/BPH and ED -- Second-Line Evaluation -- Treatment of LUTS/BPH and ED -- Education and Lifestyle Modifications -- Phosphodiesterase Type 5 Inhibitors -- Tadalafil -- Efficacy of Action of PDE5I Monotherapy in ED-LUTS/BPH -- Combined Therapy With α-Adrenergic Antagonists and PDE5i -- Other PDE5I Therapies (Not Approved by Current Guidelines for ED-LUTS/BPH) -- Sildenafil -- Vardenafil -- Avanafil -- Mirodenafil -- Udenafil -- Effects of Drugs Used for LUTS on Erectile Function -- Conclusive Remarks -- References -- Chapter 5: Metabolic Syndrome and LUTS/BPH -- Introduction -- Metabolic Syndrome: Definition and Prevalence -- MetS and BPH: Preclinical Evidences and Pathophysiology -- MetS and LUTS/BPE: The Role of Inflammation -- Prostate Size and Shape: The Influence of MetS -- The Correlation Between MetS and LUTS -- Diet and Lifestyle in Men With MetS and LUTS Due to BPE -- Basis for Medical Treatment in Men With MetS and LUTS/BPE -- The Impact of MetS on the Outcomes of BPH Surgery -- Conclusions -- References -- Chapter 6: Diagnostic Work-up of LUTS/BPH: From Standard to New Perspectives -- Introduction -- Diagnostic Workup of LUTS/BPH -- Standard Diagnostic Tests -- History -- Symptom Questionnaires -- Frequency Volume Charts and Bladder Diaries -- Physical Examination and Digital-Rectal Examination -- Urinalysis -- Blood Analysis. , PVR Urine -- Uroflowmetry -- Imaging -- Urethro-Cystoscopy -- Computer-Urodynamic Investigation -- New Diagnostic Perspectives -- Ultrasound Measurement of IPP -- Ultrasound Measurement of DWT -- References -- Further Reading -- Chapter 7: Phytotherapy in Benign Prostatic Hyperplasia -- Introduction -- Serenoa Repens -- Mechanism of Action -- Variability of Products and Extraction Techniques -- Clinical Studies -- Safety Profile -- Conclusion -- Pygenum Africanum -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Urtica Dioica -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Conclusion -- Cucurbita Pepo -- Mechanism of Action -- Clinical Studies -- Safety Profile -- Hypoxis Rooperi -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Rye Grass Pollen -- Mechanism of Action -- Clinical Studies -- Safety Profile and Conclusion -- Conclusion -- References -- Chapter 8: Medical Aspects of the Treatment of LUTS/BPH: Alpha-Blockers -- Introduction -- Pathophysiology and Mechanisms of Action of Alpha-Blockers in BPH -- Pathophysiology of LUTS/BPH/BPO: Reviewing Alpha-Adrenoreceptors as a Valuable Therapeutic Target -- Potential Action of Alpha-Blockers on BPO -- Potential Effects of Alpha-Blockers on Storage Symptoms and Bladder Function -- Potential Effects of Alpha-Blockers on Nocturia -- Types of Alpha-Adrenergic Blockers: Family Members -- Efficacy -- Global Efficacy on LUTS (IPSS), Quality of Life, and Placebo Effect -- Effects on BPO (Qmax, Urodynamics, and Postvoid Residuals) -- Efficacy on the Long Term and Treatment Adherence -- Intermittent Treatment -- Dose Adjustments -- Safety and Tolerability -- Clinical Use -- General Indications/Single Therapy -- Associations -- Conclusion -- References. , Chapter 9: Medical Aspects of the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: 5-Alpha Reducta ... -- Mechanism of Action -- Testosterone and Dihydrotestosterone -- 5-Alpha Reductase Enzyme Family -- Rationale for 5-Alpha Reductase Inhibition in BPH -- 5-Alpha Reductase Inhibitors -- Finasteride -- Dutasteride -- 5-ARI for the Treatment of BPH -- Indications for Treatment of BPH With 5-ARI -- Clinical Effects of BPH Treatment With 5-ARI -- Finasteride Versus Dutasteride for the Treatment of BPH -- Sexual Side Effects of 5-Alpha Reductase Inhibitor Use -- Combination Therapy With 5-ARI and Alpha-1 Adrenergic Receptor Blockers for the Treatment of BPH -- 5-ARI for Hematuria and Bleeding During Transurethral Resection of the Prostate in Men With BPH -- 5-ARI for the Prevention and Treatment of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Prevention of Prostate Cancer -- 5-Alpha Reductase Inhibition for the Treatment of Prostate Cancer -- References -- Chapter 10: Medical Aspects of the Treatment of LUTS/BPH: Antimuscarinic and β3-Agonists -- Keypoints -- Introduction -- Antimuscarinics -- Mechanism of Action -- Efficacy -- Adverse Events -- β3-Agonists -- Mechanism of Action -- Efficacy -- Adverse Events -- Conclusions -- References -- Chapter 11: Medical Aspects of the Treatment of LUTS/BPH: Combination Therapies -- Introduction -- AB+5ARI -- Anticholinergic Agents and AB -- Tolterodine and AB -- Solifenacin Succinate and AB -- Fesoterodine and AB -- β3-Adrenoreceptor Agonist Mirabegron and AB -- Phosphodiesterase-Type-5 Inhibitors and 5ARI or AB -- Plant Extracts/Phytotherapy and Other Agents -- References -- Chapter 12: Surgical Management of LUTS/BPH: TURP vs. Open Prostatectomy -- History of Surgical Treatment for Benign Prostatic Hyperplasia (BPH) -- Pathophysiology of BPH. , Epidemiology and Socioeconomic Burden of Surgical Treatment for BPH -- Factors Affecting Choice of Surgery Type -- Prostate Size -- Surgeon Preference and Hospital Setting -- Patient Age -- Prostatectomy -- Simple Prostatectomy -- Robot-Assisted Laparoscopic Approaches -- TUR of the Prostate -- Monopolar TURP -- Bipolar TURP -- Outcomes -- Symptoms -- Dysuria -- Urgency -- IPSS Improvement -- Quality of Life -- Physiological Measures -- Peak Flow Rate Improvement -- Residual Urinary Volume Reduction -- Perioperative Outcomes -- Bleeding -- Resected Prostate Weight -- Postoperative Fever -- Time to Catheter Removal -- Hospital Stay and Return Time to Work -- Urinary Tract Infection -- Epididymitis -- Retreatment Rate -- Re-operation -- Adverse Events -- Incontinence -- Impotence -- Bladder Neck Contracture -- TUR Syndrome -- Conclusion -- References -- Chapter 13: Surgical Treatment for LUTS/BPH: Laser Devices -- Introduction -- Lasers Typically Used for Vaporization -- GreenLight Laser -- Diode Lasers -- Lasers Typically Used for Resection/Enucleation -- Thulium Lasers -- Holmium:YAG Lasers -- Enucleation for BPO: Techniques and Results -- Holmium Laser Enucleation of the Prostate -- Principles of Surgical Technique -- Results -- Complications -- Thulium Laser Enucleation of the Prostate (ThuLEP) -- Principles of Surgical Technique -- Results -- Complications -- Greenlight Laser Enucleation of the Prostate (GreenLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Diode Laser Enucleation of the Prostate (DiLEP) -- Principles of Surgical Technique -- Results -- Complications -- Learning Curve -- Eraser Laser Enucleation of the Prostate (ELEP) -- Principles of Surgical Technique -- Results -- Complications -- Laser Ablation for Benign Prostatic Enlargement: Techniques and Results. , Holmium Laser Ablation of the Prostate.

Additional Edition: ISBN 0-12-811397-9

Language: English